Discover
IMUX
Immunic, Inc.
8.19
2 x 6.15
2 x 9.76
bid
ask
+
0.63
8.33%
2 @ 04:00 PM
8.19 +0.00 (0.00%)
| Ytd | 53.37% | |
| 1y | -10.98% |
7.47
day range
8.59
5.06
52 week range
17.43
| Open | 7.55 | Prev Close | 7.56 | Low | 7.47 | High | 8.59 | Mkt Cap | 111.75M |
| Vol | 512.18K | Avg Vol | 290.60K | EPS | -3.83 | P/E | N/A | Forward P/E | -1.67 |
| Beta | 1.45 | Short Ratio | 4.69 | Inst. Own | 64.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 12.62 | 200-d Avg | 11.40 | 1yr Est | 12.79 |
IMUX News
proactiveinvestors.com
Immunic to present four vidofludimus calcium abstracts at MSToronto2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said four abstracts on its lead MS drug candidate, vidofludimus
benzinga.com
Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Me
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel
prnewswire.com
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto
– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Mul